Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-? (FR?) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

For an abdominal wall hernia repair, also known as a ventral hernia repair, the most common surgical approaches have been ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

President Donald Trump’s pick to lead the National Institutes of Health answered sharp questions in a confirmation hearing ...

Women who suffer greater menopause symptoms are more likely to experience memory and thinking problems as they age, research ...

Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two pa ...